Erectile Dysfunction Drug Market By Drug Class (PDE5 Inhibitors {Sildenafil, Tadalafil, Vardenafil, Avanafil}, Testosterone Replacement Therapy {Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate, Other }, Prostaglandin E1 {Injectables, Urethral Suppositories}, Others), By Route of Administration (Oral, Injectables, Topical, Implants, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Clinics), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Drug Class

• PDE5 Inhibitors
  • Sildenafil
  • Tadalafil
  • Vardenafil
  • Avanafil
• Testosterone Replacement Therapy
  • Testosterone Enanthate
  • Testosterone Cypionate
  • Testosterone Propionate
  • Other
• Prostaglandin E1
  • Injectables
  • Urethral Suppositories
• Others

By Route of Administration

• Oral
• Injectables
• Topical
• Implants
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Clinics

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Pfizer Inc.
• Eli Lilly and Co.
• Bayer AG
• Teva Pharmaceuticals
• Viatris
• Apotex Inc.
• Endo International PLC
• Zydus Cadila
• Cipla Ltd.
• Aurobindo Pharma
• Sun Pharmaceutical Industries Ltd.
• Novartis
• Vivus Inc.
• Hetero Drugs Ltd.
• Menarini Group
• Astellas Pharma Inc.
• Bausch Health Companies Inc.